Document is current
Any future updates will be listed below
-
Authors
Kirchhoff, Florian P https://orcid.org/0000-0002-5144-5531
Steinhelfer, Lisa
Pfob, Christian H.
Lapa, Constantin
Hartrampf, Philipp E.
Buck, Andreas K.
Tauber, Robert
Schäfer, Hannah
Schmaderer, Christoph
Fütterer, Cornelia
Haller, Bernhard
Jahnen, Matthias
Knorr, Karina
Gschwend, Jürgen E.
Weber, Wolfgang A.
Eiber, Matthias
Lunger, Lukas
-
Funding
Funding for this research was provided by:
Technische Universität München
- License Information
-
More Information
Article History
Received: 13 November 2025
Accepted: 8 April 2026
First Online: 16 April 2026
Declarations
:
: This study was performed in line with the principles of the Declaration of Helsinki. Approval was granted by the Ethics Committee of the Technical University Munich (references 115/18S, 2020-40, 20200609 01).
: There are no individual person’s data published in this manuscript.
: Informed consent was obtained from all individual participants included in the study.
: ME reports fees from Blue Earth Diagnostics Ltd. (consultant, research funding), Novartis/AAA (consultant, speaker), Telix (consultant), Bayer (consultant, research funding), RayzeBio (consultant), Point Biopharma (consultant), Eckert-Ziegler (speaker) and Janssen Pharmaceuticals (consultant, speakers bureau), Parexel (image review) and Bioclinica (image review) outside the submitted work and a patent application for rhPSMA. He and other inventors are entitled to royalties on sales of POSLUMA ® . LL reports his employment at Boehringer Ingelheim International GmbH. CL reports prior consulting activities for Blue Earth Diagnostics Ltd., PentixaPharm, Pfizer, and Novartis. WW reports to be an editor in this journal.
: The other authors declare no conflict of interest.
